

①②

EUROPEAN PATENT APPLICATION

②① Application number: **78100264.7**

⑤① Int. Cl.²: **C 07 D 241/32, A 61 K 31/495**

②② Date of filing: **28.06.78**

③③ Priority: **29.06.77 US 811011**

④③ Date of publication of application:
10.01.79 Bulletin 79/01

⑥④ Designated Contracting States:
BE CH DE FR GB LU NL SE

⑦① Applicant: **Merck & Co., Inc.,**
Patent Department 126 East Lincoln Avenue,
Rahway, N.J. 07065 (US)

⑦② Inventor: **Woltersdorf, Otto William, jr.,**
200 Dorset Way,
Chalfont, Pa. (US)

⑦② Inventor: **deSolms, Susan Jane,**
735 Port Indian Road,
Norristown, Pa. (US)

⑦② Inventor: **Cragoe, Edward Jethro, jr.,**
2211 Oak Terrace Drive,
Lansdale, Pa. (US)

⑦④ Representative: **Abitz, Walter, Dr. Ing. et al.,**
Abitz, Morf, Gritschneider P.O. Box 890109,
D-8000 München 86 (DE)

⑤④ **Process for preparing amiloride and other new 6-substituted derivatives.**

⑤⑦ **N-Amidino-3,5- diamino-6- substituted-2- pyrazinecarboxamides and a process for their synthesis.**

EP 0 000 200 A1

- 1 -

16044

1 TITLE OF THE INVENTION

PROCESS FOR PREPARING AMILORIDE AND OTHER NEW
6-SUBSTITUTED DERIVATIVES

5 SUMMARY AND BACKGROUND OF THE INVENTION


This invention relates to a novel process for preparing N-amidino-3,5-diamino-6-substituted-2-pyrazinecarboxamide particularly the N-amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide which
10 is commercially known as amiloride. Also included are several novel N-amidino-3,5-diamino-6-substituted-2-pyrazinecarboxamides. These compounds are useful because they possess diuretic and naturetic properties. They differ from most of the known, effective
15 diuretic agents, however, in that the compounds of this invention selectively enhance the excretion of sodium ions without causing an increase in excretion of potassium ions. The potassium loss, which is caused by known diuretics, often results in a severe
20 muscular weakness. Since the compounds of this invention are essentially free of this potassium depletion, they have this decided advantage as diuretics. As diuretic agents, they can be used for the treatment of edema, hypertension and other
25 diseases known to be responsive to this therapy.

1 In some instances it may be desirable to
make a salt of these compounds, using a pharmaceutically
acceptable acid, and these salts are to be considered
as included in this invention and in the scope of
5 the claims.

The products of this invention can be
administered to man or animals in the form of pills,
tablets, capsules, elixirs, injectable preparations
and the like and can comprise one or more of the
10 compounds of this invention as the only essential
active ingredient of the pharmaceutical formulation
or, as mentioned above, the novel compound(s) can be
combined in pharmaceutical formulations with other
diuretic agents or, indeed, other therapeutic agents.

15 The compounds of this invention are
advantageously administered at a dosage range of from
about 5 mg./day to about 750 mg./day or at a somewhat
higher or lower dosage at the physician's discretion,
preferably in subdivided amounts on a 2 to 4 times
20 a day regimen.


Particular compounds which can be prepared
according to the process of this invention are shown
below in Formula I.



I

30 wherein X is Cl (this would be amiloride), CN, CH₃S,
CF₃S or C₆H₅S.

1 The novel process used to prepare these compounds is depicted in the following flow sheet:



Generally the process shown as going from compound IV to II to I concerns the reaction of N-amidino-5-diamino-6-iodo (or 6-bromo)-2-pyrazine-carboxamide shown in Formula II and being described in the prior art particularly U.S. Patent 3,318,813 with Cu X salts wherein X is as previously defined.

This reaction can be run in a solvent, particularly an inert organic solvent and preferably hexamethylphosphonamide or dimethylformamide. The reaction temperature is not critical and the reaction can be run at anywhere from 25 - 100°C. The length of time the reaction is carried out is not critical either and can be run anywhere from 0.5 to 10 hours.

1 Isolation of the reaction product which is
N-amidino-3,5-diamino-6-X-2-pyrazinecarboxamide
from the reaction mixture is performed by methods
known in the art such as by adding crushed ice and
5 water to the reaction mixture to precipitate the
desired product.

An alternative route to the compounds of
this invention involves the reaction of CuX wherein
X is as defined above with lower alkyl (methyl)-3,5-
10 diamino-6-iodo-(or bromo)-pyrazinoate which in turn
under similar reaction conditions as discussed for
the first reaction above will provide lower alkyl-
3,5-diamino-6-substituted pyrazinoate. This is
shown in the above flow sheet as a reaction of IV to
15 III. Compound IV is known from the literature
particularly U. S. Patent 3,313,813. The lower
alkyl 3,5-diamino-6-X-pyrazinoate (Compound III) can
then be reacted with guanidine to yield the desired
product Compound I. This latter reaction is prefer-
20 ably carried out under anhydrous conditions with or
without a solvent such as methanol, ethanol, isopropyl
alcohol or other solvents. The reaction may be
carried out at room temperature or by heating on a
steam bath for 1 minute to 2 hours or longer. The
25 desired product usually is recovered from the cooled
reaction mixture by trituration with water. Purifi-
cation frequently is carried out by converting the
product to a salt which can be recrystallized or
the base can be regenerated by addition of aqueous
30 alkali.

The following examples illustrate but do
not limit the preparation of the various compositions
of the invention.

Methyl 3,5-diamino-6-iodo-2-pyrazinoate
25 (370 mg., 0.0012 mole), cuprous cyanide (215 mg.,
0.0024 mole) and hexamethylphosphoramide (10 ml.)
are combined and heated at 100°C. for 15 minutes.
After cooling to 25°C. the reaction mixture is
added to aqueous sodium cyanide solution, stirred
30 at 25°C. for 1 hour and extracted with CHCl_3 . The
 CHCl_3 layer was washed with dilute NaCN solution,
then with H_2O , and dried (MgSO_4). After evaporation
of the CHCl_3 , the residual oil was treated with
hexane to give 75 mg. of methyl 3,5-diamino-6-iodo-2-pyrazinoate
35 2-pyrazinoate hemihydrate melting at 244-5.

- 1 Elemental analysis for $C_7H_7N_5O_2 \cdot 1/2 H_2O$;
Calc.: C, 41.59; H, 3.99; N, 34.64;
Found: C, 42.81, H, 3.99; N, 34.09.

5 EXAMPLE 3

Preparation of N-Amidino-3,5-diamino-6-trifluoro-
methylthio-2-pyrazinecarboxamide

Step A.: Methyl 3,5-diamino-6-trifluoromethyl-
thio-2-pyrazinoate

- 10 Methyl 3,5-diamino-6-iodo-2-pyrazinoate
(3.70 g., 0.0012 mole), cuprous trifluoromethylmer-
captide (5.0 g., 0.0025 mole) and hexamethylphosphor-
amide (100 ml.) are combined and heated at 100°C. for
15 minutes. The reaction mixture is added to crushed
15 ice - H_2O and extracted with $CHCl_3$, the $CHCl_3$ layer
washed with water, dried ($MgSO_4$) then concentrated
to give an amber oil. The oil is dissolved
in ether, extracted several times with H_2O , dried
($MgSO_4$) then concentrated to an oil which solidifies
20 on trituration with butyl chloride to give 1.26 g.
of methyl 3,5-diamino-6-trifluoromethylthio-2-
pyrazinoate, m.p. 151-5°C.

Elemental analysis for $C_7H_7F_3N_4O_2S$:

- Calc.: C, 31.35; H, 2.63; N, 20.89; S, 11.95;
25 Found: C, 31.04; H, 2.67; N, 19.65; S, 11.95.

Step B.: N-Amidino-3,5-diamino-6-trifluoro-
methylthio-2-pyrazinecarboxamide
hydrate

- Guanidine hydrochloride (3.34 g., 0.035
30 mole) is added to a solution of sodium methoxide
(1.67 g., 0.032 mole) in methanol (20 ml.) with
stirring at 25°C. After 15 minutes, methyl 3,5-di-
amino-6-trifluoromethylthio-2-pyrazinoate (1.85
g., 0.007 mole) is added, and the mixture is heated

1 on a steam bath for 15 min. Crushed ice- H_2O
(20 ml.) is added to the reaction mixture to
precipitate 390 mg. of N-amidino-3,5-diamino-
6-trifluoromethylthio-2-pyrazinecarboxamide,
5 m.p. 195°C.

Elemental analysis for $C_7H_8F_3N_7OS \cdot H_2O$;

Calc.: C, 26.84; H, 3.22; F, 18.19;

Found: C, 27.09; H, 3.18; F, 17.49.

10

EXAMPLE 4

Step A.: Methyl 3,5-diamino-6-trifluoromethyl-
thio-2-pyrazinoate

Methyl 3,5-diamino-6-trifluoromethylthio-2-
pyrazinoate is prepared from methyl 3,5-diamino-6-
15 iodo-2-pyrazinoate following essentially the same
procedure described in Example 3, Step A except that
dimethylformamide is used as the solvent.

EXAMPLE 5

20 Step A.: Methyl 3,5-diamino-6-trifluoromethyl-
thio-2-pyrazinoate

Methyl 3,5-diamino-6-trifluoromethylthio-2-
pyrazinoate is prepared from methyl 3,5-diamino-6-
iodo-2-pyrazinate following essentially the same
25 procedure described in Example 3, Step A except that
bis(trifluoromethylthio)-mercury and copper are used
to generate cuprous trifluoromethylthiomercaptide
in situ.

30

EXAMPLE 6

Step A.: N-Amidino-3,5-diamino-6-trifluoro-
methylthio-2-pyrazinecarboxamide

N-Amidino-3,5-diamino-6-trifluoromethyl-
thio-2-pyrazinecarboxamide is prepared from

- 1 N-amidino-3,5-diamino-6-iodo-2-pyrazinecarboxamide hydrochloride by essentially the same procedure described in Example 1 using trifluoromethylthio-copper in place of cuprous cyanide.

5

EXAMPLE 7

Preparation of N-Amidino-3,5-diamino-6-methylthio-2-pyrazinecarboxamidehydrochloridehydrate

- 10 Step A.: Methyl 3,5-diamino-6-methylthio-pyrazinoate

A solution of methyl 3,5-diamino-6-iodo-pyrazinoate (14 g., 0.048 mole) and cuprous methyl-mercaptide (12 g., 0.108 mole) in hexamethylphosphoramide (100 ml.) is heated on a steam bath with
15 stirring for 1-1/2 hours, poured into ice water (0.5 l) extracted with chloroform, washed with water, dried over $MgSO_4$ and evaporated at reduced pressure. Treatment of the residue with hexane gives 2.0 g. of methyl 3,5-diamino-6-methylthiopyrazinoate which
20 melts at 158-60°C. after purification by chromatography on silica gel; eluent 50% benzene-ethyl acetate.

Elemental analysis for $C_7H_{10}N_4O_2S$:

- Calc.: C, 39.25; H, 4.70; N, 26.16;
25 Found: C, 40.16; H, 4.93; N, 26.58.

Step B.: N-Amidino-3,5-diamino-6-methylthio-2-pyrazinecarboxamide hydrochloride hydrate

- Guanidine hydrochloride (1.5 g., 0.016
30 mole) is added to a solution of sodium methoxide (0.75 g., 0.014 mole) in methanol (25 ml.), stirred for five minutes and filtered free of sodium

- 1 chloride. The guanidine solution is evaporated
to 5 ml. then treated with methyl 3,5-diamino-
6-methylthiopyrazinoate (0.6 g., 0.0028 mole)
heated on a steam bath for five minutes, treated
5 with water (10 ml.) and acidified with hydrochloric
acid to give 0.6 g. of N-amidino-3,5-diamino-6-
methylthio-2-pyrazinecarboxamide hydrochloride
hydrate which melts at 170°C.
Elemental analysis for $C_7H_{11}N_7OS \cdot HCl \cdot H_2O$;
10 Calc.: C, 28.42; H, 4.77; N, 33.15; Cl, 11.98;
Found: C, 28.62; H, 4.44; N, 32.91; Cl, 12.11.

EXAMPLE 8

- 15 Preparation of N-Amidino-3,5-diamino-6-phenylthio-
2-pyrazinecarboxamide hemihydrate

Step A.: Methyl 3,5-diamino-6-phenylthio-
pyrazinoate

- A mixture of methyl 3,5-diamino-6-iodo-
pyrazinoate (3.5 g., 0.012 mole) and cuprous phenyl-
20 mercaptide (2.3 g., 0.013 mole) in hexamethylphos-
phoramide (18 ml.) is heated on a steam bath for ten
minutes and filtered. The filtrate is poured into
300 ml. of water, and the methyl 3,5-diamino-6-phenyl-
thiopyrazinoate which separates melts at 210°C. after
25 recrystallization from 2-propanol.

Elemental analysis for $C_{12}H_{12}N_4O_2S$:

Calc.: N, 20.28; H, 4.38;

Found: N, 20.17; H, 4.40

Step B.: N-Amidino-3,5-diamino-6-phenylthio-2-pyrazinecarboxamide hemihydrate

Guanidine hydrochloride (5.2 g., 0.055 mole) is added to a solution of sodium methoxide (2.7 g., 0.50 mole) in methanol (40 ml) stirred for five minutes and filtered free of sodium chloride. The guanidine solution is evaporated to a volume of 20 ml. then treated with methyl 3,5-diamino-6-phenylthio-pyrazinoate (2.5 g., 0.009 mole), heated on a steam bath for ten minutes then poured into water (200 ml.) to give 2.2 g. N-amidino-3,5-diamino-6-phenylthio-2-pyrazinecarboxamide hemihydrate which melts at 238°C. after being washed with methanol. Elemental analysis for $C_{12}H_{13}N_7OS \cdot 1/2 H_2O$:

15 Calc.: C, 46.14; H, 4.52; N, 31.39;
 Found: C, 46.15; H, 4.59; N, 31.41.

EXAMPLE 9

20 Preparation of N-Amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide

N-Amidino-3,5-diamino-6-iodo-2-pyrazinecarboxamide (1.61 g., 0.005 mole), cuprous chloride (1.19 g., 0.012 mole) and hexamethylphosphoramide (15 ml.) are heated at 100°C for 10 minutes. The mixture is cooled to 25°C. then added to aqueous sodium cyanide solution and extracted with $CHCl_3$. On evaporating the $CHCl_3$ and triturating the oily residue with hexane there is obtained N-amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide, m.p. 30 241°C.

Elemental analysis for $C_6H_8ClN_7O$;


Calc.: C, 31.38; H, 3.51; N, 42.70; Cl, 15.44;

Found: C, 31.59; H, 3.43; N, 42.85; Cl, 15.42.

1 WHAT IS CLAIMED IS:


1. A compound of the formula:

5


10 wherein X is CN, CH₃S, CF₃S or C₆H₅S.

2. A process for preparing compounds of the formula:

15

20 wherein X is Cl, CN, CH₃S, CF₃S or C₆H₅S
which comprises reacting a compound of the formula:

25




with CuX

wherein X is as previously defined and Y is I or Br.

1 3. A process of claim 2 wherein the
reaction is carried out in the solvent hexamethyl-
phosphoramide or dimethylformamide at 25 - 100°C.

5 4. A process for preparing compounds
of the formula



which comprises

a) reacting a compound of the formula:



20 with CuX
wherein X is Cl, CN, CH₃S, CF₃S or C₆H₅S and Y is I
or Br to produce a compound of the formula:



wherein X is as previously defined and
30 b) reacting the product of step a) with
guanidine to yield the desired compounds.

- 1 5. A process of claim 4 wherein the
reaction of step a) is carried out in the presence
of hexamethylphosphoramide or dimethylformamide
at 25-100°C.

5



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	US - A - 3 305 552 (MERCK) * Columns 1 to 4, 9 *	1, 2, 4	C 07 D 241/32 A 61 K 31/495
	REAGENTS FOR ORGANIC SYNTHESIS Louis F. Fieser & Mary Fieser, J. Wiley (1967) * Page 391-2 *	2, 3, 5	
	REAGENTS FOR ORGANIC SYNTHESIS, vol. 5, Louis F. Fieser & Mary Fieser, J. Wiley (1975) * Page 167 *	2, 3, 5	TECHNICAL FIELDS SEARCHED (Int. Cl.)
	METHODEN DER ORGANISCHEN CHEMIE, Houben-Weyl, Band V/3, Halogenverbindungen (Chlorverbindungen Herstellung) Georg Thieme Verlag (1962) * Page 946, paragraph 3; page 947 *	2, 3, 5	C 07 D 241/32
			CATEGORY OF CITED DOCUMENTS
			X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons
			&: member of the same patent family, corresponding document
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
The Hague	22-09-1978	FRANCOIS	